NSB NeuroScientific Biopharmaceuticals Limited
Healthcare · Biotechnology
· website
$0.06
52wk 0.06 – 0.24
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About NeuroScientific Biopharmaceuticals Limited
NeuroScientific Biopharmaceuticals Limited engages in the research and development of biomedical products targeting neurodegenerative conditions. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. NeuroScientific Biopharmaceuticals Limited was incorporated in 2002 and is based in Perth, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$23.38M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.02
Dividend yield
—
Payout ratio
0.0%
Beta
1.12
EV / EBITDA
-5.04
Price / Book
1.22
ROE
-29.6%
Operating margin
-571.6%
Net margin
0.0%
Total cash
$6.36M
Total debt
$0
Current ratio
31.62
Debt / Equity
—
Free cash flow
$-305,269
Avg volume
334,689
Latest annual results
(FY ending 30 Jun 2025)
- Revenue—
- Gross profit—
- Operating income-$2.01M
- Net income-$1.85M
- Diluted EPS-0.01
- Free cash flow-$941.33K
- Net debt-$7.27M